UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdiction of in ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Matt Riley - Head, Investor Relations Al Altomari - Chairman & Chief Executive Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Agile Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a ques ...

Agile Therapeutics First Quarter 2023 Earnings Call May 11, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," "potential," "c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdiction of i ...

Agile Therapeutics Fourth Quarter & Full Year 2022 Earnings Call March 22, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," ...

Agile Therapeutics, Inc (OTCQB:AGRX) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Riley - Head, Investor Relations Al Altomari - Chairman and Chief Executive Officer Amy Welsh - Chief Commercial Officer Jason Butch - Chief Accounting Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good afternoon and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. Please note, today’s event is being reco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdictio ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Amy Welsh - Chief Commercial Officer Jason Butch - Chief Accounting Officer Conference Call Participants Oren Livnat - H.C. Wainwright Nazibur Rahman - Maxim Group LLC Operator Good afternoon, and welcome to the Agile Therapeutics Third Quarter 2022 Financial Results Conference Call. Please not ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright Operator Good afternoon, and welcome to the Agile Therapeutics Second Quarter 2022 Financial Results Conference Call. Please note, today's event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations. Matt ...